Merck posts 9% Q2 2026 revenue rise on Keytruda and vaccine sales

Merck & Co., Inc. reported its second‑quarter 2026 financial results, posting total revenue of $15.04 billion, a 9% increase compared with the same period a year earlier.

The growth was driven primarily by the oncology drug Keytruda, which generated $6.34 billion in sales, and by a 12% rise in vaccine sales, led by the HPV vaccine Gardasil.

Research and development expenses rose 15% as the company invested in its pipeline. Management reaffirmed full‑year revenue guidance of $59‑60 billion, highlighted expansion plans in emerging markets and digital initiatives, and noted a modest lift in Merck’s share price following the announcement.